Observed in our study, only partial suppression of MMPs production caused by rituximab infusions suggests that probably higher doses of this drug and/or more often administrations of these anti-CD20 antibodies are needed in treatment of RA patients refractory to anti-tumor necrosis factor blockers. Here, TNF is linked to rheumatoid arthritis.